Lori J. Wirth

Trials

Studies that name Lori J. Wirth as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:20 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05668962 · Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

  Massachusetts General Hospital · unknown · Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer · principal investigator
• Ph1
  NCT00513383 · Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

  Massachusetts General Hospital · completed · Squamous Cell Carcinoma of the Head and Neck · principal investigator
• Ph2
  NCT00095901 · Capecitabine For Nasopharyngeal Cancer

  Dana-Farber Cancer Institute · completed · Head and Neck Cancer · principal investigator
• Ph2
  NCT00052611 · Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia

  Dana-Farber Cancer Institute · completed · Head and Neck Cancer · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Administrative Core
  P30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2018 to 2026
  Named on NCT00095901, NCT00052611